MRI Supplemental to Digital Breast Tomosynthesis Averts Additional Breast Cancer Deaths

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 5, 2026.

via HealthDay

THURSDAY, March 5, 2026 -- For women aged 40 years and older with extremely dense breasts, digital breast tomosynthesis (DBT) with supplemental magnetic resonance imaging (MRI) averts additional breast cancer deaths and results in more false-positive biopsy recommendations, according to a study published online March 2 in Annals of Internal Medicine.

Anna N.A. Tosteson, Sc.D., from the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire, and colleagues examined supplemental breast MRI strategies in a simulation of women with an average to four times higher-than-average relative risk (RR) for breast cancer incidence.

The researchers found that DBT averted 7.4 to 10.5 breast cancer deaths per 1,000 average-risk women screened and 23.2 to 33.6 per 1,000 women with four times higher-than-average risk across all starting ages (40, 45, or 50 years). For women with extremely dense breasts, DBT with supplemental MRI (DBT + MRId) averted 0.1 to 0.8 additional breast cancer deaths across all RR levels and resulted in 22 to 186 additional false-positive biopsy recommendations. For women with two times higher-than-average risk, false-positive biopsies per breast cancer death averted for biennial DBT + MRId were similar to those associated with DBT in average-risk women. Biennial DBT + MRId starting at age 50 years was more effective but less cost-effective than DBT starting at age 45 years for all risk groups. In a sensitivity analysis, the incremental cost-effectiveness ratios (ICERs) were sensitive to cancer risk, MRI costs, and false-positive biopsy rates.

"Supplemental breast MRI directed to all higher-risk women (RR ≥2) with dense breasts could provide reasonable value (ICER <$100,000) if both MRI costs and false-positive biopsy recommendation rates are reduced," the authors write.

Several authors disclosed ties to the biopharmaceutical industry and/or various institutions.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-06 02:13

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords